Regarding Hepatic insufficiency, Gefitinib exhibited higher incidence rates than other EGFR-TKIs and chemotherapy, with an AST increased incidence rate of 24% and alanine ALT increased at 23%. Here, EGFR is linked to Hepatic failure.